WebOct 8, 2024 · The gold standard for the diagnosis of PD is the blood-based mass spectrometry assay for measurement of GAA activity, followed by the molecular genetic analysis of the GAA gene [5,8]. The fast and accurate diagnosis of PD is important due to the presence of pseudo-deficiency alleles and the availability of enzyme replacement … WebJul 15, 2024 · Abstract: Pompe disease (PD) is an autosomal recessive lysosomal disorder caused by the deficient activity of acid alpha-glucosidase (GAA) enzyme due to mutations in the GAA gene. The enzymatic deficiency leads to the accumulation of glycogen within the lysosomes. Clinically, the disease has been classically classified in infantile and …
Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme …
WebJul 9, 2024 · Our clinical laboratory began to offer a fluorometric dried blood spot (DBS)-based GAA activity assay for Pompe disease in 2006 after the FDA approved GAA enzyme replacement therapy in April of that year. The purpose of this study was to examine the experience of our clinical laboratory in using this assay. WebConclusions- Lower GLA and GAA enzymatic activities were associated with larger brain arterial diameters, particularly the basilar artery diameter. Lower lysosomal enzymatic … nuclear vs renewable energy
A Look at the Genetic Landscape in Pompe Disease
Acid alpha-glucosidase, also called α-1,4-glucosidase and acid maltase, is an enzyme (EC 3.2.1.20) that helps to break down glycogen in the lysosome. It is functionally similar to glycogen debranching enzyme, but is on a different chromosome, processed differently by the cell and is located in the lysosome rather than the cytosol. In humans, it is encoded by the GAA gene. Errors in th… WebGAA activity was measured in the tissue homogenates or skin fibroblast sonicates by conversion of the artificial substrate (4-MUG) to the fluorescent product umbelliferone at acidic pH 4.3. 12,... WebSep 6, 2024 · Much effort has been dedicated in the recent decades to find novel protein/enzyme-based therapies for human diseases, the major challenge of such therapies being the intracellular delivery and reaching sub-cellular organelles. One promising approach is the use of cell-penetrating peptides (CPPs) for delivering enzymes/proteins … nuclear vs fossil energy